DK0556248T3 - Mycobacterium som adjuvans til antigener - Google Patents

Mycobacterium som adjuvans til antigener

Info

Publication number
DK0556248T3
DK0556248T3 DK91919563.6T DK91919563T DK0556248T3 DK 0556248 T3 DK0556248 T3 DK 0556248T3 DK 91919563 T DK91919563 T DK 91919563T DK 0556248 T3 DK0556248 T3 DK 0556248T3
Authority
DK
Denmark
Prior art keywords
mycobacterium
antigens
adjuvant
immunoregulatry
vaccae
Prior art date
Application number
DK91919563.6T
Other languages
English (en)
Inventor
Graham Arthur William Rook
John Lawson Stanford
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909024282A external-priority patent/GB9024282D0/en
Priority claimed from GB919115410A external-priority patent/GB9115410D0/en
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of DK0556248T3 publication Critical patent/DK0556248T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK91919563.6T 1990-11-08 1991-11-08 Mycobacterium som adjuvans til antigener DK0556248T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909024282A GB9024282D0 (en) 1990-11-08 1990-11-08 Antigen carrier
GB919115410A GB9115410D0 (en) 1991-07-17 1991-07-17 Antigen carrier

Publications (1)

Publication Number Publication Date
DK0556248T3 true DK0556248T3 (da) 1997-10-27

Family

ID=26297923

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91919563.6T DK0556248T3 (da) 1990-11-08 1991-11-08 Mycobacterium som adjuvans til antigener

Country Status (11)

Country Link
US (1) US5599545A (da)
EP (1) EP0556248B1 (da)
JP (1) JPH06501479A (da)
AT (1) ATE154759T1 (da)
AU (1) AU660430B2 (da)
CA (1) CA2095855C (da)
DE (1) DE69126668T2 (da)
DK (1) DK0556248T3 (da)
ES (1) ES2104731T3 (da)
GR (1) GR3024750T3 (da)
WO (1) WO1992008488A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
BR9406496A (pt) * 1993-01-29 1996-01-02 Vetrepharm Inc Processo e composição para estimulação do sistema imunológico em um ser humano ou animal
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
WO1995024216A1 (en) * 1994-03-07 1995-09-14 Auckland Uniservices Limited Prevention of diabetes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
AU730548B2 (en) * 1996-12-18 2001-03-08 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the TH2 activity of the immune system
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2284736A1 (en) * 1997-03-28 1998-10-08 Cytoclonal Pharmaceutics, Inc. Mycobacterium recombinant vaccines
WO1998047520A1 (en) * 1997-04-24 1998-10-29 Lovelace Respiratory Research Institute Prevention and treatment of allergic disease by targeted development of protective t-helper lymphocyte immunity
CN100489105C (zh) 1997-08-05 2009-05-20 恩温塔生物制药学公司 包含hpv抗原和应激蛋白或者其表达载体的组合物激发的抗hpv抗原免疫应答
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
AU2337499A (en) * 1998-01-23 1999-08-09 National Jewish Medical And Research Center Method for treating inflammatory diseases using heat shock proteins
JP4768122B2 (ja) 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
JP4415200B2 (ja) * 1999-01-29 2010-02-17 大塚製薬株式会社 遅発育性抗酸菌ポリペプチド
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20040247622A1 (en) * 1999-06-02 2004-12-09 Genesis Research And Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003504074A (ja) * 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2396384A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
PL359930A1 (en) 2000-06-26 2004-09-06 Stressgen Biotechnologies Corporation Human papilloma virus treatment
GB0025694D0 (en) * 2000-10-19 2000-12-06 Univ London Vaccine
CN1264572C (zh) 2001-02-05 2006-07-19 斯特雷斯根生物技术公司 治疗hbv的融合蛋白及其应用
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
KR20040064688A (ko) 2001-08-20 2004-07-19 유니버시티 오브 코네티컷 헬스 센터 암 또는 전염병 치료에 유용한 열 충격 단백질 또는알파-2-마크로글로불린을 포함하는 조성물 제조 방법
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
EP1549135A4 (en) * 2002-09-20 2006-01-11 Us Agriculture VACCINE AND ADJUVANT COMPOSITIONS
CN101912288A (zh) * 2005-09-02 2010-12-15 因特赛尔美国公司 经皮递送疫苗和透皮递送药物的装置及其应用
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
KR20110009095A (ko) 2008-03-03 2011-01-27 더 유니버시티 오브 마이애미 동종 이계 암 세포-기반 면역 요법
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2975191C (en) 2015-02-06 2023-05-09 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
BR112017028163A2 (pt) 2015-06-24 2018-08-28 Immodulon Therapeutics Ltd inibidor da via de sinalização e um mycobacterium de célula inteira para o uso em terapia contra o câncer
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (da) * 1971-11-19 1975-02-07 Anvar
NL7308450A (da) * 1972-06-20 1973-12-27
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4930169A (en) * 1988-12-27 1990-06-05 Kenneth Davison Apparatus for patient hydrotherapy and manipulative treatment by a therapist
WO1990007935A1 (en) * 1989-01-23 1990-07-26 Auspharm International Ltd. Vaccine composition
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
ATE154759T1 (de) 1997-07-15
CA2095855C (en) 2003-04-29
EP0556248A1 (en) 1993-08-25
ES2104731T3 (es) 1997-10-16
DE69126668D1 (de) 1997-07-31
CA2095855A1 (en) 1992-05-09
US5599545A (en) 1997-02-04
JPH06501479A (ja) 1994-02-17
DE69126668T2 (de) 1997-10-23
AU8874191A (en) 1992-06-11
AU660430B2 (en) 1995-06-29
GR3024750T3 (en) 1997-12-31
EP0556248B1 (en) 1997-06-25
WO1992008488A1 (en) 1992-05-29

Similar Documents

Publication Publication Date Title
DK0556248T3 (da) Mycobacterium som adjuvans til antigener
NO922566D0 (no) Implantasjonsmateriale som gir naer vaskularisering
DK0777490T3 (da) Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
NO950739L (no) Vaksiner mot gruppe C Neisseria Meningtidis
NO862507D0 (no) Faste, holdbare administreringsformer med elastisk filmovertrekk.
EG18831A (en) Agents for repelling insects and mites
CA1266247C (en) ANTIBIOTIC PREPARED BY LYSOBACTER SP. SC14.067
LU88290I2 (de) Gestoden (Femovan / Femodene)
ES2027773T3 (es) Dispositivo auto-adhesivo para administracion de un principio activo por via percutanea.
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
ES8104516A1 (es) Perfeccionamientos en embragues de friccion para vehiculos automoviles
ES458197A1 (es) Un procedimiento para la preparacion de nuevos peptidoglica-nos.
ES2062035T3 (es) Metodo para la preparacion de epiclorhidrinas.
JPS53109998A (en) Preparation of miticide, gougerotin
JPS5375318A (en) Prophicactics and remedies for diarrhea of young mammals
ES2071653T3 (es) Procedimiento para preparar beta-2',2'-difluornucleosidos.
ES480904A1 (es) Un procedimiento para la produccion del antibiotico mycopla-necin.
IT1177974B (it) Composizione comprendente endotossina detossificata raffinata
JPS5435285A (en) Preparation of l-threonine by fermentation
NL189260C (nl) Werkwijze voor de bereiding van (1r,5s) 6,6-dimethyl 4(r) ((s)-cyaan-(3'-fenoxyfenyl)methoxy)-3-oxabicyclo(3,1,0)-hexanon-2.
DK0505414T3 (da) Eliminering af aktiverede lymfocytter
JPS5251634A (en) Attraction type movable vehicle with surrounding frame
SU736974A1 (ru) Искусственна стопа
SU673818A1 (ru) Вентил ционное устройство
JPS5437886A (en) Preparation of l-threonine by fermentation